Skip to main content

Astrazeneca to launch new lung cancer medicine in India



Astrazeneca to launch Osimertinib Tablet 40 mg and 80 mg (Tagrisso™) in India after it received nod from Drug Controller General of India. Also stoke pricing of the company is increased by 3 % followed by this announcement.

Osimertinib 40 mg and 80 mg (Tagrisso™) is an oral anti-cancer drug for management of lung cancer. It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy.


Osimertinib (Tagrisso™) is the product of AstraZeneca group and has been approved in over 45 countries, including US, EU, Japan, China and other Asian countries.

Astrazeneca has received import and market permission in Form 45 (Marketing Authorization) from Drug Controller General of India for Osimertinib Tablets 40 mg and 80 mg (Tagrisso™) and they will launch it on July 27, 2017.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email